Gleason Info and Partin Tables
 

The Importance of the Gleason



There is nothing in the diagnosis of prostate cancer more important than the Gleason Grade and Score. It is this one diagnostic test that all of your present and future treatment may be based on - the single most important part of your diagnosis. If the Gleason is read wrong - you may be making a mistake in your treatment decision. I Have seen men diagnosed with prostate cancer, when the slides were graded by an expert - they did not have prostate cancer. On the other hand I have seen men graded with a very low grade disease when in fact they have a very high grade and aggressive cancer. In these cases the treatment decision is always wrong if they are not read by an expert.


It is important that the reading of your biopsy slides be done by an expert to find the correct Gleason. We have found that the readings of the slides from a biopsy when done by a local pathologists is frequently wrong. We have studies that show that the errors were as high as 60% - and usually overgraded. One might say your life is dependant on the proper grading. This is not to say that the local pathologists are not good - it is just from experience we know that a select few are consistant in their findings.


A listing of experts can be found by clicking "here" .


Once the Gleason has been read by an expert you will receive a number like 3+3=6. The "6" is the Gleason Score. The 3+3 are the Gleason Grades. Now take the Gleason your PSA and your Stage and you can learn what your chances are in terms of the cancer being contained or spread elsewhere.


Now the tables have been updated as of 2007 with the knowledge gained from having treated thousands of patients, to reflect the trends in presentation and pathologic stage for men newly diagnosed with clinically localized prostate cancer at James Buchanan Brady Urological Institute. Clinicians can use these nomograms to counsel individual patients and help them make important decisions regarding their disease.  For the latest tables insert your PSA, Stage and Gleason score "here".  Below the Forum there are the Partin Tables so you can see them and place your self.


Following are the older Partin tables.


Partin Tables

KEY: BLUE numbers are from the 2001 Edition: RED is from the 1997 edition.

    2001 PSA 0.0-2.5 ng/ml / 1997 PSA 0.0-4.0
    Gleason Score Pathologic Stage Clinical Stage
    T1a T1b T1c T2a T2b T2c T3a
    2-4
    2-4    		 Organ Confined Disease
    Established Capsular Penetration
    Seminal Vesicle Involvement
    Lymph Node Involvement
    		 90(84-95)
    9 (4-15)
    0 (0-2)
    0 (0-1)
    		 80(72-86)
    19(13-26)
    1 (0-3
    0 (0-1)
    		 95(89-99)
    5 (1-11)
    -
    -
    		 91(79-98)
    9 (2-21)
    -
    -
    		 88(73-97)
    12(3-27)
    -
    -
    		 86(71-97)
    14(3-99)
    -
    -
    		 -
    -
    -
    -
    5-6
    5    		 Organ Confined Disease
    Established Capsular Penetration
    Seminal Vesicle Involvement
    Lymph Node Involvement
    		 82(73-90)
    17(9-26)
    1 (0-3)
    0 (0-2)
         		66(57-73)
    32(24-40)
    2 (0-4)
    1 (0-2)
         		90(88-93)
    9 (7-12)
    0 (0-1)
    --
    		 81(77-85)
    17(13-21)
    1 (0-2)
    0 (0-1)
    		 75(69-81)
    22(17-28)
    2 (0-3)
    1 (0-2)
    		 75(63-81)
    24(17-33)
    1 (0-4)
    1 (0-4)
    		 40(26-53)
    51(38-65)
    7 (3-14)
    2 (0-4)
    3+4=7
    6    		 Organ Confined Disease
    Established Capsular Penetration
    Seminal Vesicle Involvement
    Lymph Node Involvement
    		 78(68-88)
    19(11-29)
    1 (0-3)
    1 (0-7)
         		61(52-69)
    35(27-43)
    2 (0-4)
    2 (1-5)
         		79(84-85)
    17(13-25)
    2 (1-5)
    1 (0-2)
    		 64(56-71)
    29(23-36)
    5 (1-9)
    2 (0*5)
    		 54(46-63)
    35(28-43)
    6 (2-12)
    4 (0-10)
    		 51(38-63)
    36(26-48)
    5 (1-13)
    6 (0-18)
    		 35(22-48)
    53(41-65)
    7 (4-13)
    5 (2-9)
    4+3=7
    7    		 Organ Confined Disease
    Established Capsular Penetration
    Seminal Vesicle Involvement
    Lymph Node Involvement
    		 -
    -
    -
    -
         		43(34-53)
    44(35-54)
    6 (1-13)
    6 (2-13)
         		71(62-79)
    25(18-34)
    2 (1-5)
    1 (0-4)
    		 53(43-63)
    40(30-49)
    4 (1-9)
    3 0-8()
    		 43(33-54)
    45(35-56)
    5 (1-11)
    6 (0-14)
    		 39(26-54)
    45(32-59)
    5 (1-12)
    9 (0-26)
    		 19(11-29)
    52(40-63)
    19(10-31)
    9 (4-17)
    8-10
    8-10    		 Organ Confined Disease
    Established Capsular Penetration
    Seminal Vesicle Involvement
    Lymph Node Involvement
    		 -
    -
    -
    -
         		31(20-43)
    34(27-44)
    9 (5-16)
    4 (2-7)
         		66(54-76)
    28(20-38)
    4 (1-10)
    1 (0-4)
    		 47(35-59)
    42(32-53)
    7 (2-16)
    3 (0-9)
    		 37(26-49)
    46(35-58)
    9 (2-20)
    6 (0-16)
    		 34(21-48)
    47(33-61)
    8 (2-19)
    10(0-27)
    		 -
    -
    -
    -

    2001 PSA 2.6-4.0 ng/ml / 1997 4.1-10 ng/ml
    Gleason Score Pathologic Stage Clinical Stage
    T1a T1b T1c T2a T2b T2c T3a
    2-4
    2-4    		 Organ Confined Disease
    Established Capsular Penetration
    Seminal Vesicle Involvement
    Lymph Node Involvement
    		 84(75-82)
    14(7-3)
    1 (0-4)
    0 (0-2)
         		70(60-79)
    27(18-37)
    2 (0-6)
    1 (0-3)
         		92(82-98)
    8 (2-18)
    --
    --
    		 85(69-96)
    15(4-31)
    --
    --
    		 80(61-95)
    20(5-39)
    --
    --
    		 78(58-94)
    22(6-42)
    --
    --
    		 43(27-58)
    44(30-59)
    10(3-23)
    1 (0-5)
    5-6
    5    		 Organ Confined Disease
    Established Capsular Penetration
    Seminal Vesicle Involvement
    Lymph Node Involvement
    		 72(60-85)
    25(14-36)
    2 (0-5)
    1 (0-5)
         		53(44-63)
    42(32-51)
    3 (1-7)
    2 (1-5)
         		84(81-86)
    15(13-18)
    1 (0-1)
    --
    		 71(66-75)
    27(23-31)
    2 (1-3)
    0 (0-1)
    		 63(57-69)
    34(28-40)
    2 (1-4)
    1 (0-2)
    		 61(50-70)
    36(27-45)
    2 (1-5)
    1 (0-4)
    		 27(17-39)
    57(46-68)
    12(6-20)
    3 (1-7)
    3+4=7
    6    		 Organ Confined Disease
    Established Capsular Penetration
    Seminal Vesicle Involvement
    Lymph Node Involvement
    		 67(55-82)
    27(15-39)
    2 (0-6)
    3 (0-15)
         		47(38-57)
    44(35-53)
    3 (1-6)
    5 (2-11)
         		68(62-74)
    27(22-33)
    4 (2-7)
    1 (0-2)
    		 50(43-57)
    41(35-48)
    7 (3-12)
    2 (0-4)
    		 41(33-48)
    47(40-55)
    9 (4-15)
    3 (0-8)
    		 38(27-50)
    48(37-59)
    8 (2-17)
    5 (0-15)
    		 23(14-34)
    57(47-67)
    11(6-18)
    9 (5-15)
    4+3=7
    7    		 Organ Confined Disease
    Established Capsular Penetration
    Seminal Vesicle Involvement
    Lymph Node Involvement
    		 49(34-68)
    36(20-51)
    6 (0-19)
    8 (0-32)
         		29(21-38)
    48(38-60)
    9 (2-18)
    12(5-23)
         		58(48-67)
    37(29-46)
    4(1-7)
    1(0-3)
    		 39(30-48)
    52(43-61)
    6(2-12)
    2(0-6)
    		 30(33-39)
    57(47-67)
    7 (3-14)
    4 (0-12)
    		 27(18-40)
    57(44-70)
    6 (2-16)
    7 (0-21)
    		 11(6-17)
    48(37-58)
    26(17-36)
    15(8-23)
    8-10
    8-10    		 Organ Confined Disease
    Established Capsular Penetration
    Seminal Vesicle Involvement
    Lymph Node Involvement
    		 35(18-62)
    34(17-58)
    10(0-34)
    18(0-55)
         		18(11-28)
    42(28-57)
    15(4-29)
    23(10-43)
         		52(41-63)
    40(31-50)
    6 (3-12)
    1 (0-4)
    		 33(24-44)
    53(44-63)
    10(4-18)
    3 (0-8)
    		 25(17-34)
    57(46-68)
    12(5-22)
    5 (0-14)
    		 23(14-34)
    57(44-70)
    10(3-22)
    8 (0-22)
    		 6 (3-10)
    34(24-46)
    35(23-48)
    24(13-38)



      2001 PSA 4.1-6.0 ng/ml
      Gleason Score Pathologic Stage Clinical Stage
      T1c T2a T2b T2c
      2-4
      		 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement







      		90(788-98)
      10(2-22)
      -
      -
      		 81(63-95)
      19(5-37)
      -
      -
      		 75(55-93)
      25(7-45)
      -
      -
      		 75(52-93)
      27(7-48)
      -
      -



      5-6 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement







      		80(78-83)
      19(6-21)
      1 (0-1)
      0 (0-1)
      		 66(62-70)
      32(28-36)
      1 (1-2)
      1 (0-2()
      		 57(52-63)
      39(33-44)
      2 (1-3)
      2 (1-3)
      		 55(44-64)
      40(32-80)
      2 (1-4)
      3 (1-7)



      3+4=7 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement







      		63(58-68)
      32(27-36)
      3 (2-5)
      2 (1-3)
      		 44(39-50)
      46(40-52)
      5 (3-8)
      4 (2-7)
      		 35(29-40)
      51(44-57)
      4 (4-11)
      7 (4-15)
      		 31(25-41)
      50(40-60)
      6(2-11)
      12(5-25)



      4+3=7 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement







      		52(43-60)
      42(35-50)
      3 (1-6)
      3 (1-5)
      		 33(25-41)
      56(48-64)
      5 (2-8)
      6 (3-11)
      		 25(18-52)
      60(50-68)
      5 (3-9)
      10(5-18)
      		 21(14-31)
      57(43-68)
      4 (1-10)
      16(6-32)



      8-10 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement







      		46(36-56)
      45(36-54)
      5 (3-9)
      3 (1-6)
      		 28(20-37)
      58(49-66)
      8 (4-13)
      6 (2-12)
      		 21(14-29)
      59(49-69)
      9 (4-16)
      10(4-20)
      		 18(11-28)
      57(43-70)
      7 (2-15)
      16(6-33)



      2001 PSA 6.1-10.0 ng/ml
      Gleason Score Pathologic Stage Clinical Stage
      T1c T2a T2b T2c
      2-4
      		 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement







      		87(73-97)
      13B3-27 -
      -
      		 76(56-94)
      24(6-44)
      -
      -
      		 69(47-91)
      31(9-53)
      -
      -
      		 67(45-91)
      33(9-55)
      -
      -



      5-6
      		 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement







      		75(72-77)
      25(21-25)
      2 (2-3)
      0 (0-1)
      		 58(54-61)
      37(34-41)
      4 (3-5)
      1 (0-2)
      		 49(43-54)
      44(39-49)
      5 (3-8)
      2 (1-3)
      		 46(36-56)
      49(37-55)
      5 (2-9)
      3 (1-6)



      3+4=7
      		 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement







      		54(49-59)
      35(32-40)
      8 (6-1)
      2 (2-3)
      		 35(30-40)
      49(43-54)
      13(9-18)
      3 (2-6)
      		 26(22-31)
      52(46-58)
      16(10-22)
      6 (4-10)
      		 24(17-32)
      52.42-61()
      13(6-25)
      10(5-18)



      4+3=7
      		 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement







      		43(35-51)
      47(40-54)
      8 (4-12)
      2 (1-4)
      		 25(19-32)
      58(51-66)
      11(6-17)
      5 (2-8)
      		 16(52-68)
      60(7-20)
      8 (5-14)
      9 (6-13)
      		 16(10-24)
      58(46-69)
      11(4-21)
      13(6-25)



      8-10
      		 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement







      		37(28-46)
      48(39-57)
      13(8-19)
      3 (1-5)
      		 21(15-28)
      57(48-65)
      17(11-26)
      5 (2-10)
      		 15(10-21)
      57(48-67)
      19(11-29)
      8 (4-16)
      		 13(8-20)
      56(43-69)
      16(5-26)
      6 (3-10)





      2001 PSA OVER 10 / 1997 PSA 10.1-20.0 ng/ml
      Gleason Score Pathologic Stage Clinical Stage
      T1a T1b T1c T2a T2b T2c T3a
      2-4
      2-4      		 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement
      		 76(65-88)
      20(10-32)
      2 (0-7)
      0 (0-7)
             		61(47-78)
      33(18-47)
      3 (0-9)
      3 (0-14)
             		80(61-95)
      20(5-39)
      -
      -
      		 65(43-89)
      35(11-57)
      -
      -
      		 57(35-86)
      43(14-65)
      -
      -
      		 54(32-85)
      46(15-68)
      -
      -
      		 -
      -
      -
      -
      5-6
      5      		 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement
      		 61(47-78)
      33(18-47)
      3 (0-9)
      3 (0-14)
             		40(31-50)
      50(39-59)
      5 (1-10)
      5 (2-11)
             		62(58-64)
      33(30-36)
      4 (3.5)
      2 (1.3)
      		 42(38-46)
      47(43-52)
      6 (4-8)
      4 (3-7)
      		 33(28-38)
      52(46-56)
      8 (5-11)
      8 (5-12)
      		 30(21-38)
      51(42-60)
      6 (2-12)
      13(6-22)
      		 18(10-27)
      59(47-69)
      15(8-25)
      7 (3-15)
      3+4=7
      6      		 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement
      		 -
      -
      -
      -
      		33(25-42)
      49(38-59)
      4 (1-8)
      13(6-24)
             		37(32-42)
      43(38-48)
      12(9-17)
      8 (5-11)
      		 20(17-24)
      49(43-55)
      16(11-22)
      14(9-21)
      		 14(11-17)
      48(40-53)
      17(12-24)
      22(15-30)
      		 11(7-17)
      42(30-55)
      13(6.24)
      33(18-49)
      		 14(8-22)
      54(44-64)
      14(8-21)
      18(10-27)
      4+3=7
      7      		 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement
      		 33(19-57)
      38(18-61)
      8 (0-28)
      18(0-57)
             		17(11-24)
      46(34-60)
      11(3-22)
      24(10-41)
             		27(21-34)
      51(44-59)
      11(6-17)
      10(5-17)
      		 14(10-18)
      55(46-64)
      13(7-20)
      18(10-27)
      		 9 (6-13)
      50(40-60)
      13(8-21)
      27(16-39)
      		 7 64-12()
      43(29-59)
      10(3-20)
      38(20-58)
      		 6 (3-10)
      40(30-50)
      28(18-39)
      26(16-38)
      8-10
      8-10      		 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement
      		 -
      -
      -
      -
             		9 (5-16)
      33(21-51)
      15(4-32)
      40(19-60)
             		22(16-30)
      50(42-59)
      17(10-25)
      11(5-18)
      		 11(7-15)
      52(41-62)
      19(12-29)
      17(9-29)
      		 7 (4-10)
      46(36-59)
      19(12-29)
      27(14-40)
      		 6 (3-10)
      41(27-57)
      15(5-28)
      38(20-59)
      		 3 (1-5)
      26(17-37)
      34(21-47)
      37(24-52)

      PSA > 20.0 ng/ml
      Gleason Score Pathologic Stage Clinical Stage
      T1a T1b T1c T2a T2b T2c T3a
      2-4 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement
      		 -
      -
      -
      -
             		38(26-52)
      47(33-61)
      9 (1-22)
      4 (0-17)
             		58(46-68)
      34(24-44)
      7 (2-15)
      1 (0-4)
             		41(31-52)
      48(36-56)
      10(3-20)
      1(0-5)
             		29(20-40)
      52(39-65)
      14(4-29)
      3(0-11)
             		-
      -
      -
      -
             		-
      -
      -
      -
      5 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement
      		 -
      -
      -
      -
             		23(15-32)
      57(44-68)
      10(2-21)
      10(3-21)
             		40(32-49)
      48(40-56)
      9 (5-14)
      3 (1-6)
             		26(19-33)
      60(52-68)
      11(6-17)
      3 (1-7)
             		17(12-22)
      61(53-69)
      15(9-23)
      7 (3-13)
             		19(14-26)
      55(46-64)
      19(11-28)
      7 (3-13)
             		8 (4-14)
      54(40-67)
      26(14-41)
      11(4-22)
      6 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement
      		 -
      -
      -
      -
      		 17(11-25)
      51(37-64)
      8 (2-17)
      23(10-40)
             		35(27-42)
      49(43-56)
      8 (6-12)
      7 (4-11)
             		22(16-27)
      60(53-66)
      10(7-15)
      8 (5-13)
             		13(10-17)
      57(50-64)
      13(9-19)
      16(11-23)
             		15(11-20)
      51(43-59)
      17(11-24)
      17(11-25)
             		6(3-10)
      46(34-58)
      21(13-33)
      26(16-38)
      7 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement
      		 -
      -
      -
      -
             		-
      -
      -
      -
             		18(13-23)
      46(39-54)
      22(15-28)
      14(9-21)
             		10(7-14)
      51(44-58)
      24(17-32)
      14(9-22)
             		5 (4-8)
      43(35-50)
      27(20-34)
      25(18-33)
             		6 (4-9)
      37(29-45)
      32(24-42)
      25(16-34)
             		2 (1-4)
      29(19-40)
      36(25-49)
      32(20-45)
      8-10 Organ Confined Disease
      Established Capsular Penetration
      Seminal Vesicle Involvement
      Lymph Node Involvement
      		 -
      -
      -
      -
             		3 (2-7)
      24(13-42)
      20(6-43)
      51(25-72)
             		10(6-16)
      34(27-45)
      31(21-42)
      24(15-36)
             		5 (3-9)
      37(28-48)
      33(22-45)
      24(15-35)
             		3 (2-4)
      28(20-37)
      33(24-45)
      36(25-48)
             		3 (2-5)
      23(16-31)
      38(26-51)
      35(23-48)
             		1(0-2)
      17(11-26)
      40(25-55)
      42(27-58)

      Reference

      Partin AW, et al., Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.JAMA, 277(18):1445-51 1997

      Your Questions - Let Us Help    

      Site Map -      

        FOR FURTHER RESEARCH click on:  RSS Feeds  Other Links 

      This site is updated regularly, and every effort is made to ensure that the information is correct. In order to continue this web site I accept donations - click "here" for how to donate.  I do not accept any responsibility for errors or omissions that may occur.   If you find errors please notify us by clicking "here" and sending us the information.  Fair Use Notice and Warning   ©Copyright 1998 - 2008